TORONTO--(BUSINESS WIRE)--StemCellPatents.com congratulates Osiris Therapeutics for promising data reported today using the PROVACEL™, adult mesenchymal stem cell product for treatment of post myocardial infarction patients. The data, which was presented by Joshua Hare M.D. at the American College of Cardiology’s Innovation in Intervention: i2 Summit, overviewed six month follow-up of 53-patients treated in a double-blind placebo-controlled manner with intravenous administration of allogeneic stem cells. Reported results included “significantly lower rates of adverse events, such as cardiac arrhythmias, as well as significant improvements in heart, lung and overall condition.”
